Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021

The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis.

The U.S. Food and Drug Administration approved Lupkynis arlier this year as the first drug specifically developed for lupus nephritis. Up to half of people with lupus develop lupus nephritis – inflammation of the kidney – that can cause organ damage and affect kidney function.

This study result supports the use of Lupkynis for the treatment of adults with active lupus nephritis. Lupkynis was well tolerated in patients with no unexpected safety concerns and eGFR (kidney filtration rate) was stable for 36 months.

Click here for Aurinia Press Release

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates